Fig. 1. Detailed flow charts of clinical and genomic events in four patients with t(3;21). Serial BM analyses of cases 1 (A) to 4 (D) are indicated as round circles in the charts. Orange and gray circles represent BM samples analyzed and not analyzed using multigene target sequencing, respectively. All detected somatic variants are indicated in brown letters. Black circles indicate the death of a patient. Diagnosis is indicated above the timeline and treatments are indicated below the timeline as green triangles. *BM with initial detection of MECOM rearrangement.
Abbreviations: M, male; F, female; OSA, osteosarcoma; MDS-EB, myelodysplastic syndrome with excess blasts; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; t-MDS, therapy-related myelodysplastic syndrome; t-AML, therapy-related acute myeloid leukemia; APL, acute promyelocytic leukemia; MDS-U, myelodysplastic syndrome, unclassifiable; AlloPBSCT, allogenic peripheral blood stem cell transplantation; MCR, marrow complete remission; DLI, donor leukocyte infusion; GVHD, graft-versus-host disease; d/t, due to; SD, stable disease; R, remission; CR, continuous remission; DP, disease progression; P, persistent; Tx, treatment; BMI, bone marrow involvement.

Ann Lab Med 2022;42:590~596 https://doi.org/10.3343/alm.2022.42.5.590